Chat with us, powered by LiveChat

Discuss

Explore topical blogs discussing chemical safety assessment.

nitrosamine impurity risk assessment

What does the EMA update on nitrosamine impurities mean for you?

Revised guidance released by the European Medicines Agency (EMA) on 7th July sparked excitement within the scientific community. By unveiling a new system to classify nitrosamines, EMA demonstrates that regulators are supporting industry in solving the complex problem of nitrosamine impurity assessment. The new approach will benefit industry, regulators and ultimately patients. What exactly are the …

What does the EMA update on nitrosamine impurities mean for you? Read More »

A new life in Leeds at Lhasa 2

Pharmaceutical Industry and Regulators Symposium: hear from the attendees

Join us as we look back at the highly anticipated 4th instalment of the Pharmaceutical Industry and Regulators Symposium, held at the prestigious Auditório do Conselho Federal de Farmácia in Brasilia. Packed to capacity, this event was a resounding success, attracting industry experts and regulatory authorities across Brazil. What is the Pharmaceutical Industry and Regulators …

Pharmaceutical Industry and Regulators Symposium: hear from the attendees Read More »

Martyn Chilton award

Congratulations to Martyn Chilton, awarded the CTSS & RASS Top 10 Best Overall Abstract Award at SOT

We had a fantastic time at this year’s Society of Toxicology (SOT) in Nashville, Tennessee, where Principal Scientist, Dr. Martyn Chilton was shortlisted for two Best Overall Abstract awards!  Martyn was awarded ‘Top 10 Best Computational Toxicology Specialty Section (CTSS) Abstract’ and ‘Top 10 Best Risk Assessment Speciality Section (RASS) Abstract’ for his poster which …

Congratulations to Martyn Chilton, awarded the CTSS & RASS Top 10 Best Overall Abstract Award at SOT Read More »

One of the most influential scientific papers of 2022

One of the most influential scientific papers of 2022

In November last year, we published a ground-breaking article to Chemical Research in Toxicology titled ‘What Makes a Potent Nitrosamine? Statistical Validation of Expert-Derived Structure–Activity Relationships’.   Within the paper, we show that certain structural features, when treated independently, have a statistically significant impact on the carcinogenic potency of nitrosamines. It is with great excitement that …

One of the most influential scientific papers of 2022 Read More »

The benefits of joining the Complex Nitrosamines consortium

The benefits of joining the Complex Nitrosamines consortium

Data sharing initiatives allow researchers and scientists to share data and knowledge in order to improve and accelerate scientific progress and discovery. These initiatives are therefore at the heart of our Lhasa Limited ethos “Shared knowledge, shared progress“. In response to the nitrosamine crisis, we partnered with the pharmaceutical industry to launch a data sharing …

The benefits of joining the Complex Nitrosamines consortium Read More »

member benefits blog image

Passion meets purpose: The benefits of being a Lhasa Limited member

“Upon becoming a member of Lhasa Limited, a world of opportunity opened up, both for the acquisition of new tools and for opportunities to actively participate in the consortia promoted by Lhasa, where there is a very important exchange of knowledge between professionals in the field.” Mariah Ultramari, Spektra Consultoria At Lhasa, we’re proud to …

Passion meets purpose: The benefits of being a Lhasa Limited member Read More »

Lhasa Limited CEO Dr. Chris Barber reflects on 2020 and shares plans for the year ahead

Lhasa Limited CEO, Dr. Chris Barber, reflects on 2020 and shares plans for the year ahead

The global pandemic has undoubtedly had a huge impact on many companies in 2020, Lhasa is no exception. I am immensely proud of my Lhasa colleagues’ resilience during the remote working situation we all found ourselves in, demonstrated, in part, through the continued release of both software and knowledge to our members throughout 2020. If …

Lhasa Limited CEO, Dr. Chris Barber, reflects on 2020 and shares plans for the year ahead Read More »

Collaboration Innovation Working together data sharing

Anticipating and supporting the needs of our members

As a member-based organisation, anticipating and supporting the needs of our members is critical. To give context to this I’d like to highlight two examples of this in action: The development of a statistical-based methodology for the prediction of Mutagenicity; Sarah Nexus. In the mid to late 2000s individual regulators had issued guidelines allowing the …

Anticipating and supporting the needs of our members Read More »